Adagio Therapeutics (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- November 10, 2020
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $80,000,000
Company Info
- Founders
- Tillman Gerngross, Ph.D.
- Company Description
- Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments.
- Market
- Pharmaceuticals
- Location
- Waltham, MA, USA
- Coinvestors
- Fidelity Management & Research Company, GV, Mithril Capital Management, Omega Funds, OrbiMed Advisors, Polaris Partners, Population Health Partners